BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 32936674)

  • 1. PARP inhibition in treatment of pancreatic cancer.
    Hammel P; Zhang C; Matile J; Colle E; Hadj-Naceur I; Gagaille MP; Bouattour M; Cros J; de Mestier L; Lamuraglia M
    Expert Rev Anticancer Ther; 2020 Nov; 20(11):939-945. PubMed ID: 32936674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
    Moffat GT; O'Reilly EM
    Clin Adv Hematol Oncol; 2020 Mar; 18(3):168-179. PubMed ID: 32609666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly(ADP-ribose) polymerase inhibition in pancreatic cancer.
    Singh HM; Bailey P; Hübschmann D; Berger AK; Neoptolemos JP; Jäger D; Siveke J; Springfeld C
    Genes Chromosomes Cancer; 2021 May; 60(5):373-384. PubMed ID: 33341987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging strategies in BRCA-positive pancreatic cancer.
    Kowalewski A; Szylberg Ł; Saganek M; Napiontek W; Antosik P; Grzanka D
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1503-1507. PubMed ID: 29777302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting DNA damage repair pathways in pancreas cancer.
    Crowley F; Park W; O'Reilly EM
    Cancer Metastasis Rev; 2021 Sep; 40(3):891-908. PubMed ID: 34403012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors.
    Miller AL; Fehling SC; Garcia PL; Gamblin TL; Council LN; van Waardenburg RCAM; Yang ES; Bradner JE; Yoon KJ
    EBioMedicine; 2019 Jun; 44():419-430. PubMed ID: 31126889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
    Roger E; Gout J; Arnold F; Beutel AK; Müller M; Abaei A; Barth TFE; Rasche V; Seufferlein T; Perkhofer L; Kleger A
    Cells; 2020 Sep; 9(9):. PubMed ID: 32948057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models.
    Golan T; Stossel C; Atias D; Buzhor E; Halperin S; Cohen K; Raitses-Gurevich M; Glick Y; Raskin S; Yehuda D; Feldman A; Schvimer M; Friedman E; Karni R; Wilson JM; Denroche RE; Lungu I; Bartlett JMS; Mbabaali F; Gallinger S; Berger R
    Int J Cancer; 2018 Jul; 143(1):179-183. PubMed ID: 29396858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.
    Sorscher S; Ramkissoon S
    Oncologist; 2021 Nov; 26(11):916-918. PubMed ID: 34309133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes.
    Momtaz P; O'Connor CA; Chou JF; Capanu M; Park W; Bandlamudi C; Berger MF; Kelsen DP; Suehnholz SP; Chakravarty D; Yu KH; Varghese AM; Zervoudakis A; Li J; Ku GY; Park JS; Shcherba M; Harding JJ; Goldberg Z; Abou-Alfa GK; Salo-Mullen EE; Stadler ZK; Iacobuzio-Donahue CA; O'Reilly EM
    Cancer; 2021 Dec; 127(23):4393-4402. PubMed ID: 34351646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting.
    Stossel C; Raitses-Gurevich M; Atias D; Beller T; Glick Gorman Y; Halperin S; Peer E; Denroche RE; Zhang A; Notta F; Wilson JM; O'Kane GM; Haimov Talmoud E; Amison N; Schvimer M; Salpeter SJ; Bar V; Zundelevich A; Tirosh I; Tal R; Dinstag G; Kinar Y; Eliezer Y; Ben-David U; Gavert NS; Straussman R; Gallinger SJ; Berger R; Golan T
    Cancer Discov; 2023 Aug; 13(8):1826-1843. PubMed ID: 37449843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New drug approval: Olaparib - pancreatic cancer with BRCA germline mutation].
    Hilmi M; Neuzillet C
    Bull Cancer; 2020 Oct; 107(10):961-962. PubMed ID: 32943226
    [No Abstract]   [Full Text] [Related]  

  • 13. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.
    Pishvaian MJ; Biankin AV; Bailey P; Chang DK; Laheru D; Wolfgang CL; Brody JR
    Br J Cancer; 2017 Apr; 116(8):1021-1026. PubMed ID: 28291774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA mutations in pancreatic cancer and progress in their targeting.
    Alkassis S; Yazdanpanah O; Philip PA
    Expert Opin Ther Targets; 2021 Jul; 25(7):547-557. PubMed ID: 34289788
    [No Abstract]   [Full Text] [Related]  

  • 15. Next-generation therapies for pancreatic cancer.
    Buckley CW; O'Reilly EM
    Expert Rev Gastroenterol Hepatol; 2024; 18(1-3):55-72. PubMed ID: 38415709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP Inhibitor Sensitizes
    Kim C; Kim D; Lee DS; Lee S; Yoo C; Kim KP
    Anticancer Res; 2023 Dec; 43(12):5523-5534. PubMed ID: 38030179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer.
    Gout J; Perkhofer L; Morawe M; Arnold F; Ihle M; Biber S; Lange S; Roger E; Kraus JM; Stifter K; Hahn SA; Zamperone A; Engleitner T; Müller M; Walter K; Rodriguez-Aznar E; Sainz B; Hermann PC; Hessmann E; Müller S; Azoitei N; Lechel A; Liebau S; Wagner M; Simeone DM; Kestler HA; Seufferlein T; Wiesmüller L; Rad R; Frappart PO; Kleger A
    Gut; 2021 Apr; 70(4):743-760. PubMed ID: 32873698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-derived xenograft models of BRCA-associated pancreatic cancers.
    Golan T; Atias D; Stossel C; Raitses-Gurevich M
    Adv Drug Deliv Rev; 2021 Apr; 171():257-265. PubMed ID: 33617901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.
    Lowery MA; Kelsen DP; Capanu M; Smith SC; Lee JW; Stadler ZK; Moore MJ; Kindler HL; Golan T; Segal A; Maynard H; Hollywood E; Moynahan M; Salo-Mullen EE; Do RKG; Chen AP; Yu KH; Tang LH; O'Reilly EM
    Eur J Cancer; 2018 Jan; 89():19-26. PubMed ID: 29223478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond BRCA: Diagnosis and management of homologous recombination repair deficient pancreatic cancer.
    LaRose M; Manji GA; Bates SE
    Semin Oncol; 2024; 51(1-2):36-44. PubMed ID: 38171988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.